Maintain pressure on reforms to protect NHSDiabetes drug may increase cardiovascular risk
Data has suggested an increased risk of cardiovascular problems for diabetes patients treated with the drug rosiglitazone (Avandia, Avandamet), the Medicines and Healthcare products Regulatory Agency has warned.
It said a Europe-wide review of the drug was under way, but until the results were known the MHRA advised healthcare professionals to closely observe contraindications and monitoring requirements for rosiglitazone, and to use alternatives where possible.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.